SIM0417

DRUG2 trials

Sponsors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Conditions

COVID-19Healthy Male Volunteers

Phase 1

Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants

CompletedNCT05475834

Jiangsu Simcere Pharmaceutical Co., Ltd.Healthy Male Volunteers

Start: 2022-07-21End: 2022-08-07Updated: 2022-10-03

Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19

CompletedNCT05506176

Jiangsu Simcere Pharmaceutical Co., Ltd.COVID-19

Start: 2022-08-19End: 2023-03-21Updated: 2023-05-06

Related Papers

Model-informed drug development in public health emergency of international concern: accelerating marketing authorization of simnotrelvir

Antimicrobial Agents and Chemotherapy2025-09-18

Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

New England Journal of Medicine2024-01-1791 citations

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.

2023-07-1121 citations